Poly I:C primes the suppressive function of human palatine tonsil-derived MSCs against Th17 differentiation by...

Area of Science:

• Immunology
• Cell Biology
• Regenerative Medicine

Background:

• Mesenchymal stem cells (MSCs) possess immunomodulatory properties, including T cell suppression.
• The programmed death-1 (PD-1) receptor and its ligand PD-L1 pathway are crucial in regulating T cell responses.
• Understanding the mechanisms of MSC-mediated T cell suppression is vital for therapeutic applications.

Purpose of the Study:

• To investigate the role of PD-L1 in the T cell suppressive activity of human palatine tonsil-derived MSCs (T-MSCs).
• To determine the effect of polyinosinic-polycytidylic acid (poly I:C) on PD-L1 expression and T-MSC function.
• To explore the potential of pre-stimulated T-MSCs for modulating Th17 cell differentiation.

Main Methods:

• Characterization of PD-L1 expression on T-MSCs.
• Assessment of T-MSC suppressive activity on murine Th17 cell differentiation.
• Treatment of T-MSCs with poly I:C, a Toll-like receptor 3 (TLR3) ligand, followed by functional assays.

Main Results:

• Human T-MSCs constitutively express PD-L1 and suppress murine Th17 differentiation.
• Poly I:C stimulation significantly increases PD-L1 expression on T-MSCs.
• Enhanced PD-L1 expression on poly I:C-treated T-MSCs leads to augmented suppression of Th17 differentiation.

Conclusions:

• T-MSCs utilize PD-L1 to inhibit Th17 cell differentiation.
• Poly I:C pre-treatment enhances the immunomodulatory capacity of T-MSCs by upregulating PD-L1.
• Pre-stimulation of T-MSCs with poly I:C presents a promising strategy for therapeutic modulation of Th17-dominant immune responses.